| A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. | |
| | |
MedLine Citation:
|
PMID: 10752986 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this study was to develop a model for predicting the occurrence of life-threatening neutropenia (LN, ANC < or = 0.5 x 10(9)/l) and febrile neutropenia (FN, an ANC < 0.5x10(9)/l in association with a body temperature of > or = 38.3 degrees C) after the first cycle of CHOP therapy in patients newly diagnosed with aggressive NHL. One hundred and forty-five patients, aged > or = 15 years, with newly diagnosed diffuse mixed, diffuse large-cell or large-cell immunoblastic lymphoma (IWF categories, F, G, H), who had been treated with CHOP at King Chulalongkorn Memorial Hospital between June 1994 and December 1998, were entered into the study. The criteria for eligibility included complete work-up for baseline evaluation, treatment with standard CHOP chemotherapy, at least one complete blood count performed during days 8-14 post-treatment or if at any time the patients experienced a BT of > or = 38.3 degrees C and were not treated with any colony-stimulating factors (CSFs). The median age of the patients was 47 years (range, 17-78). Forty-eight percent of the patients were in stage III/IV, 36% had ECOG performance status (PS) II-IV, 30% had > or = 2 extranodal diseases, 59% had serum LDH > 1 x normal and 23% had bone marrow involvement. The frequencies of patients in the low-, low-intermediate, high-intermediate and high risk groups according to the international index were 29%, 28%, 17% and 26%, respectively. Thirty-nine percent of the patients had LN at nadir and 33% developed FN after the first course of CHOP. By using stepwise logistic regression analysis, the pretreatment variables independently predictive of the LN at nadir and the FN were serum albumin concentration of < or = 3.5 g/dl, serum LDH > 1 x normal and whether there was bone marrow involvement of lymphoma at presentation. The model, based on the incorporation of these three factors, identified three risk groups of patients with a predicted probability of developing LN at nadir of 81.5% (95% CI, 68.5-90.7) (high risk), 23.9% (95% CI, 12.6-38.8) (intermediate risk) and 4.4% (95% CI, 0.5-15.1) (low risk). The predicted rate of FN in the three groups were 72.2% (95% CI, 58.4-83.5), 17.4% (95% CI, 7.8-31.4) and 2.2% (95% CI, 0.05-11.8), respectively. In conclusion, our model could be used as a means to identify patients with newly diagnosed aggressive NHL, treated with CHOP, who are at high risk (> or = 50% probability) of developing post-first course LN and FN, in whom CSF and/or antibiotic prophylaxis might be indicated. |
| | |
Authors:
|
T Intragumtornchai; J Sutheesophon; P Sutcharitchan; D Swasdikul |
Related Documents
:
|
9053496 - Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the es... 12605176 - The effects of an awareness-raising program for patients and primary care physicians on... 15613556 - Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis d... 20138566 - Multivariate analyses to assess the effect of surgeon volume on survival rate in oral c... 12573746 - Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful b... 7981446 - Oral contraceptive use and the prognosis of breast cancer. |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 37 ISSN: 1042-8194 ISO Abbreviation: Leuk. Lymphoma Publication Date: 2000 Apr |
Date Detail:
|
Created Date: 2000-08-03 Completed Date: 2000-08-03 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 351-60 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. itanin@netserv.chula.ac.th |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Cyclophosphamide / adverse effects, therapeutic use Doxorubicin / adverse effects, therapeutic use Female Fever / chemically induced, epidemiology* Humans Incidence Logistic Models Lymphoma, Non-Hodgkin / drug therapy* Male Middle Aged Neutropenia / chemically induced, epidemiology* Predictive Value of Tests Prednisone / adverse effects, therapeutic use Vincristine / adverse effects, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/CHOP protocol; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women.
Next Document: Human herpesviruses in primary ocular lymphoma.